Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 2:28 AM
Ignite Modification Date: 2025-12-25 @ 2:28 AM
NCT ID: NCT02440334
Eligibility Criteria: Inclusion Criteria: * Previously received cryotherapy of RCC. * Be scheduled for contrast-enhanced MRI/CT to monitoring of RCC recurrence as part of their 8, 12, 18, 24, or 36 month CT/MRI follow up. * Be at least 18 years of age. * Be medically stable. * If a female of child-bearing age, must have a negative pregnancy test. * Have signed Informed Consent to participate in the study. Exclusion Criteria: * Females who are pregnant or nursing. * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example: * Patients on life support or in a critical care unit. * Patients with unstable occlusive disease (eg, crescendo angina) * Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia. * Patients with uncontrolled congestive heart failure (NYHA Class IV) * Patients with recent cerebral hemorrhage. * Patients with known sensitivities to albumin, blood, or blood products * Patients who have undergone surgery within 24 hours prior to the study sonographic examination. * Patients with known hypersensitivity to perflutren * Patients with cardiac shunts. * Patients with congenital heart defects. * Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli. * Patients with respiratory distress syndrome.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT02440334
Study Brief:
Protocol Section: NCT02440334